RAPT Therapeutics to Participate in Two Investor Conferences in March

Rhea-AI Summary

SOUTH SAN FRANCISCO, Calif., March 3, 2021 - RAPT Therapeutics (Nasdaq: RAPT) announced CEO Brian Wong will speak at two investor conferences this month. The H.C. Wainwright Global Life Sciences Conference features a company presentation available on March 9 at 7:00 am ET. Wong will also participate in the 33rd Annual Roth Conference on March 15 at 2:00 pm ET, discussing novel immuno-oncology targets. RAPT specializes in oral small molecule therapies for oncology and inflammatory diseases, focusing on advanced drug candidates like FLX475 and RPT193.

SOUTH SAN FRANCISCO, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will participate in the following investor conferences in March:

• H.C. Wainwright Global Life Sciences Conference – A recording of the company presentation will be available Tuesday, March 9, 2021 at 7:00 am Eastern Time.
  
  
• 33rd Annual Roth Conference – Featured panelist on “Novel Immuno-Oncology Targets That Could Improve Clinical Outcomes” panel March 15, 2021 at 2:00 pm Eastern Time.
  

To access the live panel webcast or subsequent archived recording of the panel or company presentation, please visit the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations.

About RAPT Therapeutics, Inc.
RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively. The Company is also pursuing a range of targets that are in the discovery stage of development.

Investor Contact:
Sylvia Wheeler
swheeler@wheelhouselsa.com

Media Contact:
Aljanae Reynolds
areynolds@wheelhouselsa.com

FAQ

What are the upcoming conferences RAPT Therapeutics will participate in?

RAPT Therapeutics will participate in the H.C. Wainwright Global Life Sciences Conference on March 9, 2021, and the 33rd Annual Roth Conference on March 15, 2021.

What time will RAPT's presentation be available during the H.C. Wainwright Global Life Sciences Conference?

The presentation will be available on March 9, 2021, at 7:00 am Eastern Time.

When is the panel discussion featuring RAPT's CEO Brian Wong?

Brian Wong will be a featured panelist at the 33rd Annual Roth Conference on March 15, 2021, at 2:00 pm Eastern Time.

What is the focus of RAPT Therapeutics?

RAPT Therapeutics focuses on discovering and developing oral small molecule therapies for oncology and inflammatory diseases.

What drug candidates is RAPT Therapeutics developing?

RAPT is developing FLX475 and RPT193, targeting C-C motif chemokine receptor 4 (CCR4) for the treatment of cancer and inflammation.